N1174: Phase I/Comparative Randomized Phase II Trial of TRC105 plus Bevacizumab versus Bevacizumab in Bevacizumab-Naïve Patients with Recurrent Glioblastoma Multiforme

ID Number 13-1046-01174

Principal Investigator(s)
Adilia Hormigo

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this research is to study any good and bad effects of combining bevacizumab with another chemotherapy drug called TRC105, and comparing the combination to the usual approach which is chemotherapy with bevacizumab alone.  TRC 105 is not approved by the FDA for the treatment of glioblastoma multiforme and its use in this research study is investigational.

Contact Information
Dr. Adilia Hormigo
(212) 824-7309

Recruiting Patients: No